Subtype
Thyroid Gland Carcinoma
CI-CAN-00006937THCAExplore in graph →
96 active trials8 approved drugs53 evidence items
- NCIt
- C4815
- DOID
- 3963
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006937THCAExplore in graph →
Clinical trials
389 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (42)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06790589 | COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer | not yet recruiting | Phase 2 | 70 | AHS Cancer Control AlbertaOTHER | 0 | Feb 6, 2026 | clinicaltrials |
| NCT07391514 | Deep Learning-Based Intraoperative Dual-tracer Video Analysis of Sentinel Lymph Node Mapping for Metastasis Prediction in cN0 Papillary Thyroid Carcinoma | completed | — | 131 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 |
| Feb 6, 2026 |
| clinicaltrials |
| NCT04459273 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers(FAPI PET RDRC) | active not recruiting | Phase 1 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06235814 | Molecular Analysis for Precision Surgery in Thyroid Cancer Trial(MAPS) | completed | N/A | 2 | University of California, Los AngelesOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07383246 | CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC(CAST-MTC) | recruiting | Phase 3 | 150 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06440850 | Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation | recruiting | Phase 2 | 21 | City of Hope Medical CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06639191 | [177Lu]Lu-AKIR001 First-in-human Study(AKIR001) | recruiting | Early Phase 1 | 15 | Karolinska University HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05014698 | IDEntification of New Predisposition Genes in Differentiated THYroid Cancer(IDENTHY-K) | terminated | N/A | 34 | Nantes University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04593277 | Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study | completed | N/A | 549 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07357571 | Preoperative Prediction of Lymph Node Metastasis in T1N0M0 Papillary Thyroid Carcinoma by Using Contrast-enhanced Ultrasound | recruiting | — | 600 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07359586 | Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia | recruiting | — | 1,200 | Zhejiang UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07354698 | Application of Mitoxantrone Hydrochloride Injection in Transoral Robotic Thyroid Cancer Surgery(MHI) | not yet recruiting | Phase 4 | 114 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06133374 | Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples | recruiting | — | 130 | University of CalgaryOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT03899792 | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors(LIBRETTO-121) | active not recruiting | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 11 | Jan 6, 2026 | clinicaltrials |
| NCT07314255 | The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma(ZL2025) | active not recruiting | — | 60 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07299318 | Multimodal Deep Learning for Lymph Node Metastasis in Thyroid Cancer | not yet recruiting | — | 3,200 | West China HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06623578 | Comparative Study of Transaxillary Robotic Thyroidectomy With MRND Versus Conventional Open Surgery in N1b PTC | recruiting | N/A | 876 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04624477 | Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer | active not recruiting | — | 450 | University Health Network, TorontoOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 40 | AccSalus Biosciences, Inc.INDUSTRY | 0 | Nov 28, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05668585 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | completed | Phase 1 | 89 | C4 Therapeutics, Inc.INDUSTRY | 5 | Nov 21, 2025 | clinicaltrials |
| NCT05024929 | Targeted Therapy to Increase RAI Uptake in Metastatic DTC | recruiting | — | 32 | Children's Hospital of PhiladelphiaOTHER | 2 | Nov 14, 2025 | clinicaltrials |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | terminated | Phase 2 | 23 | Day One Biopharmaceuticals, Inc.INDUSTRY | 7 | Oct 2, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT06270082 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | terminated | Phase 1 | 75 | Ikena OncologyINDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04462471 | Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers | completed | Phase 1 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06374602 | Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer | recruiting | Phase 2 | 20 | Saint Petersburg State University, RussiaOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT01896479 | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer(EXAMINER) | active not recruiting | Phase 4 | 247 | ExelixisINDUSTRY | 14 | Sep 2, 2025 | clinicaltrials |
| NCT06439745 | More Than 50% of Unifocal cN0 T1b/Small T2 Papillary Thyroid Carcinoma May Require Completion Thyroidectomy if Nodal Status is Evaluated(cN0PTC) | completed | — | 314 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Sep 2, 2025 | clinicaltrials |
| NCT02973997 | Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) | completed | Phase 2 | 57 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT01723202 | Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer | completed | Phase 2 | 53 | Bhavana KondaOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06359847 | Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer | recruiting | Phase 2 | 60 | Beijing Scitech-Mq Pharmaceuticals LimitedINDUSTRY | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07138716 | Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC | recruiting | N/A | 30 | Luo YapingOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07138261 | Taiwanese Anaplastic Thyroid Cancer Registry(TATC) | not yet recruiting | — | 100 | National Health Research Institutes, TaiwanOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT05752669 | Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.(TEMPEST) | completed | — | 100 | Istituto Auxologico ItalianoOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT07107503 | 10 Years' Follow-up Results of Ultrasound-guided Radiofrequency Ablation Versus Surgery for Low-risk Papillary Thyroid Micro-carcinoma | completed | — | 757 | Yi MaoOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT04197960 | Microwave Ablation and Surgical Resection for Micropapillary Thyroid Carcinoma | completed | N/A | 973 | Chinese PLA General HospitalOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07066644 | Intraoperative Pathologic Evaluation of Central Lymph Nodes in Papillary Thyroid Carcinoma | completed | — | 509 | Seoul National University HospitalOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07072143 | An International Study on Pediatric Patients With Rare Tumors.(PARTNER) | recruiting | — | 6,250 | Azienda Ospedaliera di PadovaOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07062211 | Diagnostic Accuracy of Fluorodeoxyglucose-18 PET in the Evaluation of RPTC With Patient's Raised Thyroglobulin Level | active not recruiting | — | 39 | Superior UniversityOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07048964 | A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations | not yet recruiting | — | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jul 3, 2025 | clinicaltrials |
| NCT07042984 | RET-US Study - Ultrasound-Based Prediction of RET Alterations and Lateral-Neck Metastasis in Thyroid Cancer(RET-US) | not yet recruiting | — | 800 | Fujian Medical UniversityOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT03469011 | A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer. | terminated | Phase 1 | 14 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT05534594 | Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer(MIMETIC) | completed | N/A | 8 | University Medical Center GroningenOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT04400474 | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study(CABATEN) | completed | Phase 2 | 93 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT02145143 | Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study | completed | Early Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT04552769 | Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer | completed | Phase 2 | 9 | Stanford UniversityOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors(ARROW) | completed | Phase 1 / Phase 2 | 590 | Hoffmann-La RocheINDUSTRY | 13 | May 31, 2025 | clinicaltrials |
| NCT04129411 | Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation | completed | N/A | 5 | Mayo ClinicOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06254859 | Intraoperative Neuromuscular Monitoring and Its Impact on Pre- and Postoperative Acoustic Outcomes in Thyroid Surgery | recruiting | — | 100 | Fujian Medical UniversityOTHER | 1 | May 20, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Feb 6, 2026source: clinicaltrials